Interferon beta-1b (Betaseron, BAY86-5046)

DRUG19 trials

Sponsors

Bayer

Conditions

Clinically Isolated SystemMultiple SclerosisMultiple Sclerosis, Chronic ProgressiveMultiple Sclerosis, Relapsing-RemittingRelapsing Remitting MS (RRMS)Relapsing Remitting Multiple Sclerosis (RRMS)Relapsing-Remitting Multiple SclerosisSecondary Progressive MS (SPMS)

Phase 3

BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study

CompletedNCT00185211

BayerMultiple Sclerosis

Start: 2002-08-31End: 2008-05-31Updated: 2013-12-30

Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis

CompletedNCT00370071

BayerMultiple Sclerosis

Start: 2006-11-30End: 2008-09-30Updated: 2015-10-29

BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose

CompletedNCT00459667

BayerMultiple Sclerosis, Relapsing-Remitting

Start: 2007-05-31End: 2008-03-31Updated: 2015-04-23

Unknown Phase

Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis

CompletedNCT00206635

BayerMultiple Sclerosis

Start: 2005-01-31End: 2005-12-31Updated: 2012-11-22

BENEFIT Extension Study

CompletedNCT00544037

BayerMultiple Sclerosis

Start: 2007-09-30End: 2011-01-31Updated: 2012-03-05

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

CompletedNCT00787657

BayerRelapsing Remitting Multiple Sclerosis (RRMS)

Start: 2008-06-30End: 2014-10-31Updated: 2015-10-16

Physical Activity and Fatigue in Early Multiple Sclerosis (MS)

CompletedNCT00882453

BayerMultiple Sclerosis

Start: 2006-08-31End: 2011-03-31Updated: 2012-05-30

Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)

CompletedNCT00902135

BayerRelapsing-Remitting Multiple Sclerosis

Start: 2009-05-31End: 2014-08-31Updated: 2015-07-17

Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis

CompletedNCT00963833

BayerMultiple Sclerosis

Start: 2009-12-17End: 2016-09-01Updated: 2017-07-12

Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period

CompletedNCT01076595

BayerMultiple Sclerosis

Start: 2010-05-31End: 2014-07-31Updated: 2015-07-03

Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple Sclerosis

CompletedNCT01184833

BayerMultiple Sclerosis

Start: 2008-09-30End: 2011-08-31Updated: 2013-06-25

BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program

CompletedNCT01233245

BayerRelapsing Remitting MS (RRMS), Secondary Progressive MS (SPMS)

Start: 2004-04-30End: 2009-06-30Updated: 2012-11-15

Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors

CompletedNCT01235455

BayerRelapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS)

Start: 2007-08-31End: 2011-05-31Updated: 2012-11-01

Betaferon® Regulatory Post-Marketing Surveillance

CompletedNCT01414816

BayerClinically Isolated System, Multiple Sclerosis

Start: 2008-04-30End: 2012-07-31Updated: 2014-08-21

China Betaferon Adherence, Coping and Nurse Support Study

CompletedNCT01436838

BayerMultiple Sclerosis, Chronic Progressive

Start: 2012-03-31End: 2015-12-31Updated: 2016-09-05

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

CompletedNCT01491100

BayerMultiple Sclerosis

Start: 2012-04-30End: 2017-04-05Updated: 2018-04-05

Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE)

CompletedNCT01706055

BayerMultiple Sclerosis

Start: 2012-09-30End: 2016-03-31Updated: 2017-03-14

Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction

CompletedNCT02652091

BayerMultiple Sclerosis, Relapsing-Remitting

Start: 2016-02-05End: 2017-09-13Updated: 2018-09-06

Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b

CompletedNCT03408093

BayerMultiple Sclerosis

Start: 2009-02-03End: 2010-03-30Updated: 2018-06-21

Related Papers

Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study.

2021-08-2311 citations

Comparative evaluation of patients' and physicians' satisfaction with interferon beta-1b therapy.

2016-09-216 citations

Adherence to Long-Term Interferon Beta-1b Injection Therapy in Patients with Multiple Sclerosis Using an Electronic Diary.

2016-04-1815 citations

Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome

Multiple Sclerosis Journal2013-07-1019 citations

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis.

2011-12-2170 citations

Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS.

2011-11-3026 citations

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.

2009-09-10243 citations

MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome.

2009-05-2014 citations

Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results.

2007-09-0136 citations

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.

2007-08-01311 citations